SeraCare Life Sciences Inc. Stock Upgraded (SRLS)

NEW YORK ( TheStreet) -- SeraCare Life (Nasdaq: SRLS) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:
  • Despite its growing revenue, the company underperformed as compared with the industry average of 10.5%. Since the same quarter one year prior, revenues slightly increased by 8.7%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • SRLS's debt-to-equity ratio is very low at 0.00 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 5.32, which clearly demonstrates the ability to cover short-term cash needs.
  • 46.50% is the gross profit margin for SERACARE LIFE SCIENCES INC which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 8.90% trails the industry average.
  • SERACARE LIFE SCIENCES INC's earnings per share declined by 37.5% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past year. However, we anticipate this trend reversing over the coming year. During the past fiscal year, SERACARE LIFE SCIENCES INC reported lower earnings of $0.14 versus $0.36 in the prior year. This year, the market expects an improvement in earnings ($0.18 versus $0.14).
  • After a year of stock price fluctuations, the net result is that SRLS's price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don't lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The stock's price rise over the last year has driven it to a level which is somewhat expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
.

SeraCare Life Sciences, Inc. provides products and services to facilitate the discovery, development, and production of human and animal diagnostics, and therapeutics. The company has a P/E ratio of 23.4, above the average drugs industry P/E ratio of 21.8 and above the S&P 500 P/E ratio of 17.7. SeraCare Life has a market cap of $61.3 million and is part of the health care sector and drugs industry. Shares are up 30.2% year to date as of the close of trading on Wednesday.

You can view the full SeraCare Life Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null